Autolus Therapeutics
AUTL
84 hedge funds and large institutions have $212M invested in Autolus Therapeutics in 2026 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 28 increasing their positions, 20 reducing their positions, and 10 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 20
15% more capital invested
Capital invested by funds: $184M → $212M (+$27.6M)
0% more funds holding
Funds holding: 84 → 84 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
0.84% less ownership
Funds ownership: 50.51% → 49.67% (-0.84%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.6M |
| 2 |
Morgan Stanley
New York
|
+$500K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$371K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$362K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$331K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
-$2.6M |
| 2 |
AC
Armistice Capital
New York
|
-$1.26M |
| 3 |
MG
Marex Group
London,
|
-$824K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$558K |
| 5 |
Renaissance Technologies
New York
|
-$494K |
AUTL Hedge Fund Activity: Q2 2026 in Review
84 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q2 2026, worth a combined $212M — up 15% from $184M a quarter earlier.
Fund positioning in AUTL was balanced in Q2 2026: 10 funds opened new positions, 10 closed out, 28 added to existing stakes and 20 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.6M. The largest seller was Schroder Investment Management Group, cutting an estimated $2.6M.
- 84 institutional investors held Autolus Therapeutics (AUTL) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $212M of Autolus Therapeutics stock for Q2 2026, up 15% quarter-over-quarter.
- 10 funds opened new Autolus Therapeutics positions in Q2 2026 and 10 closed out, a net change of 0 holders.
- The largest Autolus Therapeutics buyer in Q2 2026 was Millennium Management, an estimated $1.6M added.
- The largest Autolus Therapeutics seller in Q2 2026 was Schroder Investment Management Group, an estimated $2.6M sold.
Based on aggregated 13F filings for Q2 2026.